COLLEGEVILLE, Pennsylvania - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the European Commission has granted marketing authorization for CONBRIZA(TM) (bazedoxifene), a selective estrogen receptor modulator (SERM), for the treatment of postmenopausal osteoporosis in women at increased risk of fracture.
The World Health Organization’s (WHO) fracture risk treatment guidelines and assessment tool for calculating a woman’s risk of experiencing an osteoporotic fracture were used in analyses of clinical data that supported the approval of CONBRIZA. Wyeth was one of the first companies to apply the WHO guidelines and tool, first introduced in February 2008.
“Analyses of clinical trial data showed that treatment with CONBRIZA significantly decreased the risk of all clinical fractures and non-vertebral fractures for women who were at a greater risk of osteoporotic fracture,” says Gary L. Stiles, M.D., Executive Vice President, Chief Medical Officer, Wyeth Pharmaceuticals. “Importantly, the analyses also showed that the higher a woman’s risk of a fracture, the greater the protection she received with CONBRIZA therapy.”
Osteoporosis remains a serious public health concern, affecting more than 75 million people in Europe, the United States, and Japan. Osteoporosis is characterized by low bone mass and structural deterioration of bone tissue, leading to bone fragility and an increased risk of fractures. Up to 20 percent of a woman’s expected lifetime bone loss can occur in the years immediately following menopause.
In 2000, there were an estimated 3.79 million osteoporotic fractures in Europe, resulting in direct costs totaling an estimated euro 31.7 billion. Based on anticipated changes in European demographics, this cost is expected to increase to an estimated euro 76.7 billion by 2050.
Wyeth intends to introduce CONBRIZA in certain European markets following receipt of necessary reimbursement authorizations in those markets. Wyeth is also pursuing regulatory approval of bazedoxifene for the prevention and treatment of postmenopausal osteoporosis in the United States and other countries worldwide.
CONBRIZA Clinical Trials
The efficacy of CONBRIZA was studied in two multicenter, double-blind, randomized phase 3 clinical trials involving more than 9,000 postmenopausal women, comparing CONBRIZA to placebo and an active-control (comparator) drug. The prevention trial, conducted for two years in 1,583 patients, evaluated bone mineral density; and the treatment trial examined the incidence of new vertebral fractures in 7,492 patients for three years. Data from these studies indicated that the SERM characteristics of CONBRIZA were confirmed and further suggest a favorable endometrial profile. The most serious adverse reactions reported with CONBRIZA in these studies were venous thromboembolic events, which were more common than with placebo.
About Wyeth Pharmaceuticals
Wyeth is one of the world’s largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company’s major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.
The statements in this press release that are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In particular, there can be no assurance that CONBRIZA will be commercially successful or that CONBRIZA will be approved in the future in other formulations or indications and/or in other countries, including the United States. Other risks and uncertainties that could cause actual results to differ materially from those expressed or implied by forward looking statements include, among others, risks related to our proposed merger with Pfizer, including satisfaction of the conditions of the proposed merger on the proposed timeframe or at all, contractual restrictions on the conduct of our business included in the merger agreement, and the potential for loss of key personnel, disruption in key business activities or any impact on our relationships with third parties as a result of the announcement of the proposed merger; the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; the outcome of government investigations; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; global economic conditions; interest and currency exchange rate fluctuations and volatility in the credit and financial markets; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption “Item 1A, Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2008, which was filed with the Securities and Exchange Commission on February 27, 2009. The forward-looking statements in this press release are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
Source: Wyeth Pharmaceuticals
Media Contact: Danielle Halstrom, +1-484-865-2020, or Douglas Petkus, +1-973-660-5218, Investor Contact: Justin Victoria, +1-973-660-5340, all of Wyeth
Related Press Releases
Wyeth Presents Data from Five-Year Vertebral Fracture Prevention Study with BazedoxifeneSeptember 14th, 2009 COLLEGEVILLE, Pennsylvania -
Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announces findings from a placebo-controlled Phase 3 study of bazedoxifene 20 mg extended to five years, which indicated a significant reduction versus placebo in new vertebral fractures in postmenopausal women with osteoporosis. These and other data were presented at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting in Denver, Colo.
Patients Fear Osteoporosis Quality of Life Impact, Yet Lack Tools to Manage Concerns and Improve Osteoporosis Outcomes, New Survey SaysSeptember 13th, 2009 DENVER -
- International Osteoporosis Foundation (IOF) launches OsteoLink to address unmet needs in osteoporosis management through digital and in-person patient and physician communication networks across Europe and Australia
The International Osteoporosis Foundation (IOF) today announced results from a new multinational survey of patients (n= 844; women 55+ with post menopausal osteoporosis) and physicians (n= 837; general practitioners and specialists treating osteoporosis) at the 31st annual meeting of the American Society of Mineral and Bone Research (ASBMR). Results show that patients fear the impact of osteoporosis on quality of life, such as breaking a bone and reduced activity, far more than physicians believe.
' All Men Are Dogs, or Men Are Being Dogged Out " September 12th, 2009 A new book called, “All Men Are Dogs, or Men Are Being Dogged Out”, is a very good book to read. You need to get your copy today.
Wyeth's Torisel Approved by European Commission for the Treatment of Relapsed and/or Refractory Mantle Cell LymphomaAugust 26th, 2009 MAIDENHEAD, England - Wyeth Europa Ltd., a division of Wyeth (NYSE: WYE), announced today that the European Commission has approved the mTOR (mammalian target of rapamycin) inhibitor TORISEL(R) (temsirolimus) for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (MCL). In the European Union (EU), TORISEL is also indicated for the first-line treatment of patients with advanced renal cell carcinoma who have at least three of six prognostic risk factors.
Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment ToolsAugust 26th, 2009 BOSTON, Massachusetts and CHEADLE, England - Cardea Technology, Inc. and Optasia Medical Ltd., announce plans to collaborate and configure their software tools for Vertebral Fracture Assessment, a method for evaluating vertebral fractures from images on bone densitometers, to exchange information and create reports for the management of osteoporosis.
European CHMP Issues Positive Opinion on Wyeth's TORISEL for Treatment of Relapsed/Refractory Mantle Cell LymphomaJuly 26th, 2009 MAIDENHEAD, England - Wyeth Europa, a division of Wyeth (NYSE:WYE), announced today that it has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) recommending the approval of the mTOR (mammalian target of rapamycin) inhibitor TORISEL(R) (temsirolimus) for the treatment of relapsed and/or refractory mantle cell lymphoma (MCL). The CHMP's opinion will now be forwarded to the European Commission for a final decision.
A Supplement a Day May Help Keep Falls at BayJune 23rd, 2009 BASINGSTOKE, England -
- Help is at Hand for the Frail Elderly at Risk of Falls and Fractures via a New Medication Support Programme
As National Falls Awareness Day takes place this week, a new programme called 'Be Active' is being launched to help those already prescribed bone health supplements to take them more regularly, helping to prevent falls and reduce the burden on the NHS. Almost 3 million people suffer from osteoporosis in the UK[1] and more than 300,000 people over the age of 65 visit hospital every year because of a fracture, leaving healthcare providers saddled with around GBP2 billion worth of healthcare costs.[2] This is expected to increase to GBP2.2 billion by 2020.[3] However, according to a study carried out in the last five years, some vitamin and mineral supplements can reduce the risk of falling by up to 49%.[4]
Evidence shows benefits of supplementation [4] [5] [6] yet people who have been prescribed a bone strengthening supplement often take it incorrectly, with approximately 30% of UK patients regularly missing a prescribed dose of some vitamin and mineral supplements[7].
HRA Pharma Granted European Marketing Authorization for ellaOne(R)May 25th, 2009 PARIS - Next Generation Emergency Contraceptive Will First be Launched in UK, Germany and France as Company Expands International Operations
HRA Pharma (www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate), its next generation emergency contraceptive, has been granted marketing authorization by the European Commission. The unanimous decision by all member states enables HRA Pharma to begin marketing ellaOne throughout the European Union, making it the only approved product to have been specifically designed and developed for use as an emergency contraceptive.
Osteoporosis Drug Heritage Continues Ahead of 10th AnniversaryMay 18th, 2009 LONDON - Study Results Demonstrate Patients Continue to Adhere to Treatment With Raloxifene
To view a Vodcast of Professor Peyman Hadji presenting the data click here: 62.193.238.61/blueprinttv/expert/Expert-Opinion.html
To view a Vodcast of a Patient's Perspective click here:
62.193.238.61/blueprinttv/expert/The-Patient-Perspetive.html
Data presented today at the 8th European Congress on Menopause (EMAS) demonstrated that the majority of osteoporosis patients treated with raloxifene stay on therapy for the first two years.(1) Prof. Dr. P. Hadji, University Hospital of Giessen and Marburg GmbH, Marburg, Germany, stated that "Of the 300 postmenopausal osteoporosis patients who received treatment with raloxifene, results show that at 12, 24 and 36 months 96.4 %, 80.5% and 62% respectively of patients remained on therapy."
The data released today comes ahead of raloxifene's 10th anniversary, a turning point that will not go unmarked.
EVISTA(R) Improves Patient Compliance in Osteoporosis ManagementMay 18th, 2009 LONDON - Study Results Demonstrate Patients Adhere to Treatment Regimens With EVISTA(R)
To view a Vodcast of Professor Peyman Hadji presenting the data click the following link: 62.193.238.61/blueprinttv/expert/Expert-Opinion.html
To view a Vodcast of a Patient's Perspective click the following link: 62.193.238.61/blueprinttv/expert/The-Patient-Perspetive.html
LONDON, May 19 /PRNewswire/ --
Data presented today at the 8th European Congress on Menopause (EMAS) demonstrated that the majority of osteoporosis patients treated with EVISTA(R) (raloxifene) stay on therapy for the first two years. 300 postmenopausal osteoporosis patients received oral treatment with EVISTA(R).
Related News
Hip fractures triple elderly women's chances of dyingFebruary 4th, 2009 SYDNEY - Bone fractures, even minor ones, increase a person's chances of dying, particularly if he is elderly. But hip fractures just double the risk for women, which is three times the risk for men.
Months in space erode astronauts' bone strengthJanuary 26th, 2009 WASHINGTON - Astronauts who spend months in space tend to lose bone strength, making them increasingly vulnerable to fractures in later life. Universities of California (UC) Irvine and San Francisco evaluated 13 astronauts who spent four to six months on the International Space Station and found that, on average, their hipbone strength decreased 14 percent.
Now, test that predicts when a woman will reach menopauseMay 26th, 2009 WASHINGTON - Scientists have made a new discovery that might be of great help for women planning to have babies later in life. For the first time, scientists have been able to identify the genetic factors that influence the age at which natural menopause occurs.
Regular exercise benefits older women as much as younger womenSeptember 19th, 2009 WASHINGTON - Regular vigorous exercise benefits postmenopausal women just like younger women, according to two studies. The results were based on the studies of endurance training in 50-something women.
Aspirin improves survival in women with heart diseaseMarch 16th, 2009 WASHINGTON - Researchers have come by additional evidence that aspirin seems to reduce the risk of death in women who have heart disease or have had a stroke. The new study also provides fresh insight into aspirin dosing for women, suggesting that a lower dose of aspirin (81 mg) is as effective as a higher dose (325 mg).
Menopausal women on hormone therapy shouldn't stop treatment prior to mammogramsSeptember 29th, 2009 WASHINGTON - Researchers have suggested that menopausal women on hormone therapy (HT) shouldn't stop their treatment prior to their annual mammogram screenings. Annual mammography screening significantly reduces the breast cancer mortality in women older than 50, and is considered a pillar of routine healthcare maintenance.
Suicide risk among elderly varies according to sexSeptember 29th, 2009 WASHINGTON - Elderly men and women show different patterns of suicide, reveals a study. Louise Bradvik and Mats Berglund, from Lund University, Sweden, say that women who have tried to kill themselves several times in the past should be kept under suicide watch, as they have an increased risk of death in a future attempt.
Can sex hormone dab revive libido in post-menopausal women?January 20th, 2009 WASHINGTON - Could a dab of testosterone gell revive flagging libidos in post-menopausal women?
Researchers are testing LibiGel, dubbed the 'pink Viagra' on 3,500 women at 50 US locations, under phase III of the clinical trials, a report in Albuquerque Journal quoting Frederick Snoy, a lead investigator at one of the sites, said. In another study, researchers are enlisting women between the ages of 30 and 65, complaining of lower libido post-surgical menopause (hysterectomy and removal of the ovaries), and recipients of estrogen replacement therapy.
Studies: Popular back treatment for elderly with osteoporosis no better than fake oneAugust 5th, 2009 Back treatment for elderly no better than fake oneNEW YORK — A common treatment that uses medical cement to fix cracks in the spinal bones of elderly people worked no better than a sham treatment, the first rigorous studies of the popular procedure reveal. Pain and disability were virtually the same up to six months later, whether patients had a real treatment or a fake one.
Oral contraceptives linked to increased risk of lupusApril 8th, 2009 TORONTO - Use of oral contraceptives was linked to an increased risk of lupus, particularly among women who recently started taking them, according to a large population based study. The ratio of women to men with the autoimmune disease systemic lupus erythematosus (SLE) is nine to one and the incidence increases after puberty.
